ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Oregon » Hematology Oncology

Top Hematology Oncology Prescribers in Oregon

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
EDWARD OTTENHEIMER MD

Hematology Oncology

6,453

$792K

259
203 are 65+

26%
patients receiving schedule two controlled substances

Avg: 18%

22%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 18%

$123
Average prescription price

Avg: $430

WILLIAM PIERCE M.D.

Hematology Oncology

4,018

$2.09M

531
435 are 65+

19%
patients receiving schedule two controlled substances

Avg: 18%

15%
patients receiving schedule three controlled substances

Avg: 9%

8%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$520
Average prescription price

Avg: $430

JOHN STROTHER M.D

Hematology Oncology

1,980

$766K

296
244 are 65+

18%
patients receiving schedule two controlled substances

Avg: 18%

10%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 18%

$387
Average prescription price

Avg: $430

RALPH WEINSTEIN M.D.

Hematology Oncology

1,524

$878K

137
115 are 65+

18%
patients receiving schedule two controlled substances

Avg: 18%

11%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 18%

$576
Average prescription price

Avg: $430

PETER KENYON M.D.

Hematology Oncology

1,515

$855K

271
231 are 65+

13%
patients receiving schedule two controlled substances

Avg: 18%

9%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 18%

$564
Average prescription price

Avg: $430

CATHERINE O'BRIEN M.D.

Hematology Oncology

1,477

$494K

179
159 are 65+

18%
patients receiving schedule two controlled substances

Avg: 18%

7%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

11%
prescriptions for brand name drugs

Avg: 18%

$334
Average prescription price

Avg: $430

MICHAEL MONTICELLI MD

Hematology Oncology

1,396

$650K

229
189 are 65+

19%
patients receiving schedule two controlled substances

Avg: 18%

12%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 18%

$466
Average prescription price

Avg: $430

NATASHA TIFFANY M.D.

Hematology Oncology

1,379

$510K

199
162 are 65+

17%
patients receiving schedule two controlled substances

Avg: 18%

20%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 18%

$370
Average prescription price

Avg: $430

DANIEL GRUENBERG M.D.

Hematology Oncology

1,373

$563K

127
105 are 65+

25%
patients receiving schedule two controlled substances

Avg: 18%

18%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 18%

$410
Average prescription price

Avg: $430

GERALD GIBBS M.D.

Hematology Oncology

1,313

$320K

140
118 are 65+

26%
patients receiving schedule two controlled substances

Avg: 18%

11%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 18%

$244
Average prescription price

Avg: $430

JAE LEE MD

Hematology Oncology

1,277

$381K

191
159 are 65+

19%
patients receiving schedule two controlled substances

Avg: 18%

14%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

10%
prescriptions for brand name drugs

Avg: 18%

$298
Average prescription price

Avg: $430

JAY ANDERSEN M.D.

Hematology Oncology

1,217

$424K

178
148 are 65+

16%
patients receiving schedule two controlled substances

Avg: 18%

6%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 18%

$348
Average prescription price

Avg: $430

BRETT POISSON MD

Hematology Oncology

1,216

$963K

196
152 are 65+

24%
patients receiving schedule two controlled substances

Avg: 18%

8%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 18%

$792
Average prescription price

Avg: $430

ALISON SAVAGE MD

Hematology Oncology

1,214

$291K

208
160 are 65+

21%
patients receiving schedule two controlled substances

Avg: 18%

14%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 18%

$240
Average prescription price

Avg: $430

JEFFREY MENASHE M.D.

Hematology Oncology

1,202

$722K

186
155 are 65+

16%
patients receiving schedule two controlled substances

Avg: 18%

8%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 18%

$601
Average prescription price

Avg: $430

KEVIN YEE M.D.

Hematology Oncology

1,094

$632K

152
133 are 65+

23%
patients receiving schedule two controlled substances

Avg: 18%

10%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 18%

$578
Average prescription price

Avg: $430

ALEKSANDRA SANDER M.D.

Hematology Oncology

1,080

$555K

208
165 are 65+

15%
patients receiving schedule two controlled substances

Avg: 18%

12%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 18%

$514
Average prescription price

Avg: $430

GLENN BUCHANAN MD

Hematology Oncology

1,053

$442K

172
146 are 65+

26%
patients receiving schedule two controlled substances

Avg: 18%

16%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 18%

$420
Average prescription price

Avg: $430

MUJAHID RIZVI MD

Hematology Oncology

1,033

$781K

185
145 are 65+

17%
patients receiving schedule two controlled substances

Avg: 18%

11%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 18%

$756
Average prescription price

Avg: $430

VICKY LEE M.D.

Hematology Oncology

1,013

$301K

154
133 are 65+

14%
patients receiving schedule two controlled substances

Avg: 18%

12%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 18%

$297
Average prescription price

Avg: $430

PETER KOVACH MD

Hematology Oncology

1,012

$573K

169
143 are 65+

21%
patients receiving schedule two controlled substances

Avg: 18%

12%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 18%

$567
Average prescription price

Avg: $430

STEPHEN WILLIAMS MD

Hematology Oncology

995

$567K

183
163 are 65+

9%
patients receiving schedule two controlled substances

Avg: 18%

0%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 18%

$570
Average prescription price

Avg: $430

GABRIELLE MEYERS MD

Hematology Oncology

953

$130K

36
16 are 65+

47%
patients receiving schedule two controlled substances

Avg: 18%

0%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 18%

$136
Average prescription price

Avg: $430

SEAN HEHN MD

Hematology Oncology

941

$269K

192
167 are 65+

19%
patients receiving schedule two controlled substances

Avg: 18%

8%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 18%

$286
Average prescription price

Avg: $430

LUCY LANGER MD

Hematology Oncology

918

$31.5K

136
111 are 65+

13%
patients receiving schedule two controlled substances

Avg: 18%

0%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

7%
prescriptions for brand name drugs

Avg: 18%

$34
Average prescription price

Avg: $430

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank